Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Climb Bio is a clinical-stage biopharmaceutical company developing immunomodulatory therapeutics for inflammatory and autoimmune diseases. The company's lead asset, budoprutug, is a monoclonal antibody targeting IL-17A/F being evaluated in eosinophilic esophagitis (EoE) and potentially other eosinophilic disorders. With zero revenue, a strong balance sheet (15.16x current ratio), and recent 388% one-year stock appreciation, the company trades on clinical trial milestones and partnership potential rather than fundamentals.
Climb Bio operates a classic biotech development model: raise capital through equity offerings, invest in clinical trials to demonstrate safety/efficacy, then either commercialize independently or partner/license assets to larger pharma companies. The company's value derives from probability-weighted future cash flows from budoprutug and pipeline assets. Monetization typically occurs through regulatory approval leading to product sales, or earlier through strategic partnerships that provide upfront payments, milestones, and royalties. The IL-17A/F mechanism targets a validated pathway in inflammatory diseases, potentially offering differentiation versus single IL-17A inhibitors.
Clinical trial data readouts for budoprutug in eosinophilic esophagitis - primary endpoints on histologic response and symptom improvement
FDA regulatory interactions and guidance on clinical development pathway, including potential accelerated approval discussions
Strategic partnership announcements or licensing deals that validate platform and provide non-dilutive funding
Cash runway updates and equity financing announcements - dilution concerns versus runway extension
Competitive data from other IL-17 inhibitors or EoE therapies that establish or erode market opportunity
Pipeline expansion announcements into adjacent eosinophilic disorders or inflammatory conditions
Clinical trial failure risk - budoprutug or pipeline assets may fail to demonstrate sufficient efficacy or acceptable safety in Phase 2/3 trials, rendering the platform worthless
Regulatory approval uncertainty - FDA may require additional trials, reject applications, or impose restrictive labels that limit commercial potential
Reimbursement pressure - payers increasingly scrutinize specialty drug pricing, potentially limiting pricing power even if approved
Technology obsolescence - newer therapeutic modalities (cell therapy, gene editing) could render antibody-based approaches less competitive
Established IL-17 inhibitors from major pharma (Novartis, Eli Lilly) may expand into EoE or adjacent indications, creating well-funded competition
Multiple companies developing EoE therapies including dupilumab (Regeneron/Sanofi) already approved, creating crowded competitive landscape
Larger biotechs with superior resources can out-execute on clinical development, regulatory strategy, and commercial launch
Equity dilution risk - with negative $0.1B operating cash flow and zero revenue, future financing rounds will dilute existing shareholders significantly
Cash runway constraints - clinical trials are expensive and unpredictable; delays or additional studies required could exhaust cash before value-creating milestones
Negative ROE of -33.4% and ROA of -35.7% reflect ongoing cash consumption without offsetting revenue generation
low - Clinical-stage biotechs are largely insulated from GDP fluctuations as they generate no revenue and spending is driven by clinical trial timelines rather than economic conditions. However, severe recessions can impact ability to raise capital and affect M&A valuations. The company's $0.5B market cap with strong liquidity suggests adequate runway through near-term catalysts regardless of economic backdrop.
Rising interest rates negatively impact valuation through higher discount rates applied to distant future cash flows, which is particularly acute for pre-revenue biotechs where monetization may be 3-5+ years away. Higher rates also increase opportunity cost versus risk-free assets, reducing speculative capital flows into early-stage biotech. Additionally, rising rates can compress M&A valuations and partnership deal terms. The company's zero debt eliminates direct financing cost sensitivity, but equity financing becomes more expensive in high-rate environments.
minimal - With zero debt and 15.16x current ratio, Climb Bio has no credit risk exposure. The company funds operations through equity rather than debt markets. Credit conditions only matter indirectly through impact on biotech sector sentiment and acquirer financing capacity for potential M&A.
growth/momentum - Attracts speculative biotech investors focused on binary clinical catalysts rather than fundamental valuation. The 388% one-year return and 317% three-month return indicate momentum-driven trading around clinical milestones. Typical holders include biotech-focused hedge funds, retail investors seeking high-risk/high-reward opportunities, and event-driven funds playing clinical trial catalysts. Not suitable for value or income investors given zero revenue, negative cash flow, and no dividend. Institutional ownership likely concentrated among healthcare specialist funds.
high - Clinical-stage biotechs exhibit extreme volatility around binary events (trial readouts, FDA decisions). Small market cap ($0.5B) amplifies price swings on modest volume. Recent 317% three-month return demonstrates explosive upside potential, but downside risk is equally severe if trials fail. Beta likely exceeds 2.0x relative to broader market. Options implied volatility typically elevated. Stock can move 30-50% in single session on material news.